Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis
NCT ID: NCT02022930
Last Updated: 2016-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
510 participants
INTERVENTIONAL
2014-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hydros Joint Therapy and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis (OA)
NCT01134406
A Study to Evaluate the Clinical Performance and Safety of an Intra-articular Hyaluronic Acid in Knee Osteoarthritis
NCT03200288
The Comparison of Two Crosslinked Hyaluronate for the Treatment of Osteoarthritis Pain
NCT04000204
Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis
NCT06279507
Additional Effects of Steroid and Dextrose to Hyaluronic Acid on Knee Osteoarthritis
NCT04165902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydros
Hydros Joint Therapy
Hydros
Hydros-TA
Hydros-TA Joint Therapy
Hydros-TA
Triamcinolone acetonide
Triamcinolone acetonide
Triamcinolone Acetonide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydros
Hydros-TA
Triamcinolone Acetonide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptoms in the index knee for at least 12 months.
* Fully ambulatory Subject (ability to perform a 15 meters walk test).
* Male and female Subjects 40 through 85 years of age.
Exclusion Criteria
* Secondary OA (acute knee injury, rheumatoid arthritis, gout, history of joint infection, osteonecrosis, chronic fibromyalgia) or other chronic autoimmune disease.
* Intra articular steroid therapy in last 3 months
* Intra articular viscosupplementation in last 6 months
40 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carbylan Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Leonards, New South Wales, Australia
London, Ontario, Canada
Oshawa, , Canada
Québec, , Canada
Willemstad, Curacao, Netherlands Antilles
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COR1.1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.